Interview with Sergio Duplan, CPO Head & Country President Mexico, Novartis…
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Address: Calzada de Tlalpan #1779, Colonia San Diego Churubusco, Mexico D.F.,Mexico
Tel: (55) 5420-8600
Web: http://www.novartis.com.mx/10ybrand/NOVARTIS_WEB_2009/Soft_Templates/index.html
In Mexico, the Novartis Group consists of Novartis Pharmaceuticals, Sandoz, OTC, CIBA Vision, Novartis Animal Health, and Novartis Vaccines and Diagnostics. More than 1,700 employees and more than $7 billion MXP sales revenue in 2011.
Novartis Pharmaceuticals (patented medicines), Sandoz (generic products), OTC (prescription free medicines), CIBA Vision (provider of high technology contact lenses and their care products), Novartis Animal Health (health care for pets and livestock) and Novartis Vaccines and Diagnostics (vaccines and clinical diagnostic products).
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Fabiola Trigueros, founder and CEO at Smart Scale, explains the importance of business intelligence capabilities to undertake proper business decisions and showcases the value proposition of Smart Scale to meet…
Eduardo Gonzalez Pier, former Vice-Minister for Integration and Development of the Health Sector, shares his perspective on current dynamics in Mexico’s public health sector and highlights how collaboration between private…
Alvaro Angel, the recently appointed general manager of the pharmaceutical division of Bayer Mexico, provides insights into the rapidly evolving local pharma market, and documents Bayer Mexico’s ambitious growth strategy;…
Cédric Ertlé, managing director at Laboratoires Expanscience Mexico, explains the strategy that the affiliate has implemented to obtain 20 and 45 percent of growth in dermocosmetics and rheumatology respectively and…
Mayra Galindo Leal, general director of the Mexican Association of the Fight Against Cancer (AMLCC) provides an overview of the main milestones of this association that stands as the most…
José Angel García Hinojosa, counsellor of the board of the Grupo Loeffler Russek, details how Loeffler’s impressive growth has forced the company to increase their manufacturing capacity. While Loeffler grew…
Dr. David Kershenobich Stalnikowitz, General Director of the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán on the myriad issues surrounding diabetes in Mexico and how the Mexican healthcare…
Consuelo Albarrán, co-founder and CEO of DEFI Latina Healthcare, showcases the increasing added value brought by this leading Cofepris-authorized third party (ATP) to the pharmaceutical industry, the recent expansion of…
Rodrigo Puga, the recently appointed general manager of Pfizer Mexico, documents his strategic priorities to further strengthen the company’s performance in Mexico and consolidate Pfizer’s leadership within the Mexican market…
General Manager of Merck Mexico, Pedro Galvis, showcases the strategic importance of the Mexican affiliate within Merck’s global network and explains the importance of public-private partnerships in enhancing patient access and…
Paulina Escobedo, general manager of B. Braun Medical Mexico, provides insights into the impressive development of this division since it was set up in the country in 2011, while the…
The university spin-off UDIBI continues its unstoppable ascension: after being recently recognized by Cofepris, Mexico’s sanitary agency, as an authorized laboratory to assess biotech treatments entering the Mexican market, UDIBI…
See our Cookie Privacy Policy Here